Genfit S.A. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GNFT Nasdaq 2836 www.genfit.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Genfit S.A.

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - Jun 24th, 2025 9:08 am
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading - Jun 23rd, 2025 9:14 am
GENFIT: June 17, 2025 Combined Shareholders Meeting Results - Jun 17th, 2025 12:30 pm
GENFIT Reports First Quarter 2025 Financial Information - May 22nd, 2025 2:10 pm
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy - May 20th, 2025 2:10 pm
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) - May 14th, 2025 2:10 pm
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents - May 7th, 2025 2:10 pm
GENFIT to Present Latest ACLF Research at EASL Congress 2025 - May 4th, 2025 11:30 pm
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F - Apr 29th, 2025 1:10 pm
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025 - Apr 28th, 2025 2:10 pm
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update - Apr 24th, 2025 2:10 pm
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders - Mar 20th, 2025 3:10 pm
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs - Mar 10th, 2025 3:10 pm
GENFIT Announces Revenues and Cash Position as of December 31, 2024 - Feb 27th, 2025 2:10 pm
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting - Feb 21st, 2025 12:30 am
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders - Feb 9th, 2025 11:30 pm
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 - Feb 6th, 2025 2:10 pm
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan - Jan 30th, 2025 12:40 am
GENFIT Announces 2025 Financial Calendar - Jan 29th, 2025 2:10 pm
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - Jan 13th, 2025 2:10 pm